Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific-Site (version 1.0, dated 17-Dec-08).

Trial Profile

Apixaban for Prevention of Acute Ischemic Events - 2 A Phase 3, Randomized, Double-Blind, Evaluation of the Safety and Efficacy of Apixaban In Subjects with a Recent Acute Coronary Syndrome + Pharmacogenetics Blood Sample Amendment Number 01 - Site Specific-Site (version 1.0, dated 17-Dec-08).

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 08 Aug 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary)
  • Indications Acute coronary syndromes; Cardiovascular disorders
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms APPRAISE-2
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 11 Jul 2022 Results assessing cardiovascular outcomes in patients with DM presenting with ACS, stratified by PAD status from 4 randomized post-ACS trials (PLATO, APPRAISE-2, TRILOGY, and TRACE) published in the American Journal of Cardiology.
    • 15 Nov 2021 Results (N=47,474), pooled analysis of data from 4 multicenter randomized trials (APPRAISE-2, PLATO, TRACER and TRILOGY ACS) presented at the American Heart Association Scientific Sessions 2021
    • 05 Oct 2021 This trial has been completed in France, according to European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top